Axsome Therapeutics (AXSM) traded higher Friday, April 24, 2026, with investors focusing on a late-month U.S. regulatory catalyst: an FDA action date of April 30, 2026 for Auvelity (AXS-05) in agitation associated with Alzheimer’s disease. With the decision less than a week away, the stock’s move appears driven by event positioning and anticipation rather than a single new company press release today.

The April 30 FDA action date is tied to Auvelity’s supplemental application for agitation associated with Alzheimer’s disease. If cleared, it would expand Auvelity beyond its current commercial footprint and could materially broaden Axsome’s addressable market in CNS, a key point repeatedly highlighted in recent investor communications and market commentary around the setup into late April.

Investors also have another near-term date on the calendar: Axsome is scheduled to report first-quarter 2026 financial results on May 4, 2026 before the U.S. market opens, followed by a morning conference call. Heading into that update, traders are likely to focus on Auvelity demand trends and overall commercial execution, alongside any commentary that frames the post-April 30 trajectory.

Into the FDA date, volatility can increase as options and short-term flows adjust. Key swing factors include whether the FDA action comes on time, any labeling or post-marketing requirements, and how quickly Axsome can translate a potential new indication into prescribing momentum—followed closely by the tone and detail in management’s May 4 update.